Direct comparison
Exclusive vs. Non-Exclusive License
Exclusive vs. non-exclusive license compared: rights granted, royalty rates, diligence obligations, best-fit technologies, and march-in-rights exposure.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about Exclusive vs. Non-Exclusive License
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Exclusive License, Non-Exclusive License compare side by side?
The table below compares Exclusive License, Non-Exclusive License across 13 procurement-relevant dimensions, from number of licensees through common hybrid variant.
Side-by-side comparison
| Dimension | Exclusive License | Non-Exclusive License |
|---|---|---|
| Number of licensees | One licensee only; institution typically also gives up its own commercial-use right (though research/education-use carve-outs are common) | Multiple licensees can hold rights to the same technology simultaneously |
| Typical royalty rate | Higher per-licensee rate; academic median around 3% of net sales per a 2023 PLOS ONE study, reported ranges roughly 1%-10%, directional only | Lower per-licensee rate, often offset by royalty income from multiple licensees |
| Diligence/milestone obligations | Typically heavy -- development plan, dated milestones, progress reports, minimum spending, remedy for missed milestones | Typically minimal or none, since the institution hasn't foreclosed licensing to a more active party |
| Best-fit technology | Early-stage, capital-intensive technology requiring years of investment (e.g. a drug candidate); the basis for a single spinout company | Broadly applicable technology used by many parties -- research tools, reagents, platform software, materials |
| Bayh-Dole march-in exposure | Applies -- 35 U.S.C. Section 203 lets the funding agency compel additional licensing under four narrow statutory conditions if the licensee fails to commercialize | Not a practical concern -- multiple licensees already using the technology inherently addresses the government's practical-application interest |
| Sublicensing | Common, but only if separately granted in the agreement -- not automatic | Less common; each party typically holds only its own direct license |
| Startup / VC investment case | Usually necessary -- investors want protection from a competitor licensing the same IP | Rarely required -- there is no multi-year development gap to protect |
| Typical negotiating leverage for the institution | Higher -- equity, higher royalties and milestone payments can be extracted in exchange for exclusivity | Lower per deal -- value comes from the volume of licensees rather than per-deal leverage |
| 35 U.S.C. Section 204 U.S.-manufacturing preference | Applies -- an exclusive U.S. licensee generally must agree to manufacture substantially in the U.S. (agency-waivable) | Does not apply |
| Administrative burden | Fewer relationships per technology, but higher-stakes monitoring of one licensee's diligence | More simultaneous relationships, but lighter monitoring per licensee |
| Revenue model | Larger potential per-deal royalty or equity, concentrated in a single outcome | Smaller per-deal royalty, aggregated across many licensees |
| Risk if the licensee underperforms | High -- the technology can sit undeveloped and unavailable to anyone else absent reversion rights | Low -- other licensees, and new ones, remain available regardless |
| Common hybrid variant | Field-of-use or territory-limited exclusivity; time- or diligence-conditioned exclusivity | N/A -- non-exclusivity is already the more flexible default |
Common questions
Common questions about Exclusive License vs Non-Exclusive License
Can a license start non-exclusive and convert to exclusive later?
+
Yes. Some agreements use an option or evaluation-license structure that converts to exclusive if the licensee meets defined conditions, such as a funding or development milestone. The reverse also happens: an exclusive license can convert to non-exclusive as the contractual remedy for a licensee that misses its diligence milestones.
Does an exclusive license always produce more total revenue for the institution?
+
Not necessarily. An exclusive license typically commands a higher rate per licensee, but a non-exclusive strategy can generate comparable or greater aggregate royalty income across multiple licensees for a broadly applicable technology. The right structure depends on which approach actually gets the technology developed and used.
What is a sole license, and how is it different from an exclusive license?
+
A sole license permits only one commercial licensee, like an exclusive license, but the institution retains its own right to practice the technology -- a right a true exclusive license typically forecloses.
Is a field-of-use-limited exclusive license the same as a non-exclusive license?
+
No. A field-of-use restriction limits what the exclusive licensee can do with the technology (for example, only within veterinary diagnostics), but within that defined field the licensee is still the sole rights-holder. The institution can grant a separate exclusive license to a different party in a different field, but neither of those licenses is non-exclusive with respect to the field it actually covers.
Who decides whether a given invention should be licensed exclusively or non-exclusively?
+
The technology transfer office typically makes this call based on the nature of the technology, the size of the addressable market, and how much upfront investment a licensee will need to make before the technology reaches practical use -- see CASRAI's Patent Licensing guide for how startup versus established-company negotiating leverage factors into that decision.
